Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis.
Patients with hypereosinophilic syndrome (HES) display a very heterogeneous clinical picture ranging from asymptomatic cases to very aggressive forms. We report a 38-year-old woman with progressive HES who developed severe myelofibrosis and was treated by allogeneic stem cell transplantation, using peripheral blood (PBSCT) instead of bone marrow as the source of progenitor cells, after conditioning with cytoxan and busulphan. To the best of our knowledge, this is the first case of HES with myelofibrosis treated with PBSCT. The patient remains alive 8 months post-PBSCT, and bone marrow fibrosis has significantly decreased following transplantation. Bone Marrow Transplantation (2000) 25, 217-218.
Vazquez
L
L
Hematology Service, University Hospital of Salamanca; and Centro de Investigación del Cancer (CIC), University of Salamanca, CSIC, Spain.
Caballero
D
D
Cañizo
C D
CD
Lopez
C
C
Hernandez
R
R
Gonzalez
I
I
Flores
T
T
San Miguel
J F
JF
D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000150:complications* / Q000473:pathology / Q000628:therapy*; D055728:Primary Myelofibrosis / Q000150:complications* / Q000473:pathology / Q000628:therapy*; D019172:Transplantation Conditioning; D016896:Treatment Outcome